吉西他滨联合顺铂一线治疗复发及转移头颈部癌的疗效分析

目的评价吉西他滨联合顺铂一线治疗复发或转移头颈部癌的疗效和毒性。方法应用GP方案(吉西他滨1000mg/m2,d1,d8;顺铂20mg/m2,d1-3,21d)一线治疗复发或转移头颈部肿瘤。结果 2007年1月～2011年5月广东江门市中心医院肿瘤科有28例可评价患者,平均年龄45岁,部分缓解11例,稳定6例,总有效率和疾病控制率分别为39.29%和60.71%。疾病无进展期4～17个月,平均5.1个月,平均生存期7.4个月,1年总生存率41.7%。主要不良反应为I或II度的血液学毒性和胃肠道反应。结论吉西他滨联合顺铂一线治疗复发或转移头颈部癌显示安全、有效,且有希望延长患者的生存期。

Objective The efficacy and safety of gemcitabine in combination with cisplatin （GC） as the first-line treatment in patients with （R/M） squamous cell carcinoma of head and neck （SCCHN） were evaluated. Methods Patients with R/M SCCHN without prior treatment for their R/M disease were eligible and treated with gemcitabine 1,000 mg/m2 on day 1, day 8 and cisplatin 20 mg/m2 on day1-3 every 21 days. Results Twenty-eight patients were enrolled from January 2007 to May 2011, and 28 were evaluable for treatment effectiveness and outcome. The median age of evaluable patients was 45 years.Partial response was observed in 11 and stable disease in 6 patients. The overall response rate and disease control rate was 39.29% and 60.71%, respectively, the median time to progression （TTP） was 5.1 months, median survive time was 7.4 months and 1-year survival was 41.7%.Toxicity mainly included grade 1/2 myleosuppression,nausea/vomiting. Conclusion This GC regimen demonstrates a good activity and a promising survival period in patients with R/M SCCHN. [